<DOC>
	<DOCNO>NCT00454155</DOCNO>
	<brief_summary>The objective study follow : To demonstrate safety escalate dos opebacan subject undergo myeloablative allogeneic Hematopoietic Stem Cell Transplantation To determine pharmacokinetics opebacan subject undergo myeloablative allogeneic Hematopoietic Stem Cell Transplantation To determine IV administration opebacan associate change biological marker inflammation To develop preliminary descriptive data occurrence severity Hematopoietic Stem Cell Transplantation relate complication , include aGvHD</brief_summary>
	<brief_title>Study Opebacan Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation ( HSCT )</brief_title>
	<detailed_description>IV infusion opebacan replace endogenous BPI peritransplant period result reduction LPS-induced inflammatory sequela , particular aGvHD , patient undergo allogeneic HSCT . The rationale use opebacan patient undergo myeloablative regimen HSCT base following : Endotoxemia demonstrate play central pathophysiologic role trigger aGvHD animal model . Endotoxemia follow HSCT associated inflammatory condition ( inflammatory cytokine release ) demonstrate human associate organ damage increase morbidity mortality . Endotoxemia LBP elevation demonstrate human undergoing ablative HSCT . Chemotherapy-induced neutropenia result deficiency endogenous BPI level . The timing endotoxemic insult predictable ( i.e. , subsequent myeloablative chemotherapy radiotherapy ) . The return normal neutrophil level immediate take one week several week . Well establish laboratory technique surrogate marker relate LPS presence activity facilitate evaluation molecule design inhibit antagonize LPS effect . The objective study follow : To demonstrate safety escalate dos opebacan subject undergo myeloablative allogeneic Hematopoietic Stem Cell Transplantation To determine pharmacokinetics opebacan subject undergo myeloablative allogeneic Hematopoietic Stem Cell Transplantation To determine IV administration opebacan associate change biological marker inflammation To develop preliminary descriptive data occurrence severity Hematopoietic Stem Cell Transplantation relate complication , include aGvHD</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Age &lt; = 60 undergoing allogeneic HSCT Life expectancy &gt; 8 week Scheduled treatment condition regimen intend myeloablative Female subject childbearing age must negative urine pregnancy test . Sexually active male female subject reproductive age must use form contraception consider effective medically acceptable Investigator . Cumulative lifetime exposure &gt; 300 mg/M2 anthracycline ( express doxorubicin equivalent dose ) receipt anthracycline within 180 day prior initiate condition HSCT Active infection Prophylactic antibacterial antibiotic . Positive HIV , HTLVI , HTLVII Any prior stem cell transplant Prior history CHF Cord blood source subject 's transplanted cell .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>HSCT</keyword>
	<keyword>AGVHD</keyword>
	<keyword>Myeloablative</keyword>
	<keyword>Allogeneic</keyword>
	<keyword>Hematopoietic</keyword>
	<keyword>Stem</keyword>
	<keyword>Cell</keyword>
	<keyword>Transplantation</keyword>
</DOC>